1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management

Linyuan Wang,Xiaowen Zhang,Chunyan Ma,Nan Wu
DOI: https://doi.org/10.1016/j.intimp.2024.111835
IF: 5.714
2024-03-21
International Immunopharmacology
Abstract:Ischemia-reperfusion injury (IRI) — a complex pathological condition occurring when blood supply is abruptly restored to ischemic tissues, leading to further tissue damage — poses a significant clinical challenge. Sphingosine-1-phosphate receptors (S1PRs), a specialized set of G-protein-coupled receptors comprising five subtypes (S1PR1 to S1PR5), are prominently present in various cell membranes, including those of lymphocytes, cardiac myocytes, and endothelial cells. Increasing evidence highlights the potential of targeting S1PRs for IRI therapeutic intervention. Notably, preconditioning and postconditioning strategies involving S1PR agonists like FTY720 have demonstrated efficacy in mitigating IRI. As the synthesis of a diverse array of S1PR agonists continues, with FTY720 being a prime example, the body of experimental evidence advocating for their role in IRI treatment is expanding. Despite this progress, comprehensive reviews delineating the therapeutic landscape of S1PR agonists in IRI remain limited. This review aspires to meticulously elucidate the protective roles and mechanisms of S1PR agonists in preventing and managing IRI affecting various organs, including the heart, kidney, liver, lungs, intestines, and brain, to foster novel pharmacological approaches in clinical settings.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?